Ken Griffin Oric Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$7.52 - $11.9 $58,656 - $92,820	7,800 New	7,800 $79,000
Q1 2024 May 15, 2024	BUY	$8.04 - $16.03 $178,487 - $355,866	22,200 New	22,200 $305,000
Q3 2023 Nov 14, 2023	SELL	$6.05 - $9.28 $30,250 - $46,400	-5,000 Reduced 53.19%	4,400 $26,000
Q2 2023 Aug 14, 2023	BUY	$4.95 - $8.4 $7,425 - $12,600	1,500 Added 18.99%	9,400 $72,000
Q1 2023 May 15, 2023	SELL	$4.26 - $6.75 $172,530 - $273,375	-40,500 Reduced 83.68%	7,900 $45,000
Q4 2022 Feb 14, 2023	SELL	$2.41 - $5.89 $325,350 - $795,150	-135,000 Reduced 73.61%	48,400 $285,000
Q3 2022 Nov 14, 2022	SELL	$3.15 - $5.24 $394,065 - $655,524	-125,100 Reduced 40.55%	183,400 $587,000

124

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $323M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.